{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T14:57:05Z","timestamp":1792508225127,"version":"4.5.0"},"reference-count":46,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2020,10,1]]},"DOI":"10.1001\/jamacardio.2020.1966","type":"journal-article","created":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T12:06:26Z","timestamp":1592395586000},"page":"1182","source":"Crossref","is-referenced-by-count":126,"title":["Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease"],"prefix":"10.1001","volume":"5","author":[{"given":"Michael C.","family":"Honigberg","sequence":"first","affiliation":[{"name":"Cardiology Division, Massachusetts General Hospital, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee-Shing","family":"Chang","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren K.","family":"McGuire","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Plutzky","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital Heart and Vascular Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanita R.","family":"Aroda","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muthiah","family":"Vaduganathan","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital Heart and Vascular Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"10","key":"hrv200004r1","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1001\/jama.2015.10029","article-title":"Prevalence of and trends in diabetes among adults in the United States, 1988-2012.","volume":"314","author":"Menke","year":"2015","journal-title":"JAMA"},{"issue":"10138","key":"hrv200004r2","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1016\/S0140-6736(18)30314-3","article-title":"Trends in cause-specific mortality among adults with and without diagnosed diabetes in the USA: an epidemiological analysis of linked national survey and vital statistics data.","volume":"391","author":"Gregg","year":"2018","journal-title":"Lancet"},{"issue":"11","key":"hrv200004r3","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1161\/CIRCULATIONAHA.118.037778","article-title":"Empagliflozin reduced mortality and hospitalization for heart failure across the spectrum of cardiovascular risk in the EMPA-REG OUTCOME Trial.","volume":"139","author":"Fitchett","year":"2019","journal-title":"Circulation"},{"issue":"10","key":"hrv200004r4","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10166","key":"hrv200004r5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"issue":"4","key":"hrv200004r6","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes.","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"19","key":"hrv200004r7","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes.","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"10157","key":"hrv200004r8","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"issue":"10193","key":"hrv200004r9","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"issue":"13","key":"hrv200004r10","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes.","volume":"377","author":"Holman","year":"2017","journal-title":"N Engl J Med"},{"issue":"23","key":"hrv200004r11","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome.","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N Engl J Med"},{"issue":"9","key":"hrv200004r12","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes.","volume":"381","author":"Husain","year":"2019","journal-title":"N Engl J Med"},{"key":"hrv200004r15","doi-asserted-by":"publisher","first-page":"S111","DOI":"10.2337\/dc20-S010","article-title":"10. Cardiovascular disease and risk management: Standards of Medical Care in Diabetes\u20142020.","volume":"43","author":"American Diabetes Association","year":"2020","journal-title":"Diabetes Care"},{"issue":"24","key":"hrv200004r16","doi-asserted-by":"publisher","first-page":"3200","DOI":"10.1016\/j.jacc.2018.09.020","article-title":"2018 ACC expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways.","volume":"72","author":"Das","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"hrv200004r17","doi-asserted-by":"publisher","first-page":"69","DOI":"10.4158\/CS-2018-0535","article-title":"Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm\u20142019 executive summary.","volume":"25","author":"Garber","year":"2019","journal-title":"Endocr Pract"},{"issue":"11","key":"hrv200004r18","first-page":"e596","article-title":"2019 ACC\/AHA Guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines.","volume":"140","author":"Arnett","year":"2019","journal-title":"Circulation"},{"issue":"7","key":"hrv200004r19","doi-asserted-by":"publisher","first-page":"e294","DOI":"10.1161\/CIR.0000000000000691","article-title":"Type 2 diabetes mellitus and heart failure: a scientific statement from the American Heart Association and the Heart Failure Society of America: this statement does not represent an update of the 2017 ACC\/AHA\/HFSA heart failure guideline update.","volume":"140","author":"Dunlay","year":"2019","journal-title":"Circulation"},{"issue":"10","key":"hrv200004r20","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1002\/ejhf.v21.10","article-title":"Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology.","volume":"21","author":"Seferovic","year":"2019","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"hrv200004r21","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD.","volume":"41","author":"Cosentino","year":"2020","journal-title":"Eur Heart J"},{"issue":"7","key":"hrv200004r22","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1161\/CIRCULATIONAHA.119.041730","article-title":"Use of guideline-recommended risk reduction strategies among patients with diabetes and atherosclerotic cardiovascular disease.","volume":"140","author":"Arnold","year":"2019","journal-title":"Circulation"},{"issue":"3","key":"hrv200004r23","doi-asserted-by":"crossref","DOI":"10.1002\/edm2.76","article-title":"The prevalence of cardiovascular disease and antidiabetes treatment characteristics among a large type 2 diabetes population in the United States.","volume":"2","author":"Weng","year":"2019","journal-title":"Endocrinol Diabetes Metab"},{"issue":"12","key":"hrv200004r24","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1016\/j.jacc.2019.01.029","article-title":"Prescription of glucagon-like peptide-1 receptor agonists by cardiologists.","volume":"73","author":"Vaduganathan","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"hrv200004r25","doi-asserted-by":"publisher","first-page":"921","DOI":"10.2337\/dc19-1943","article-title":"Trends in clinical characteristics and prescribing preferences for SGLT2 inhibitors and GLP-1 receptor agonists, 2013-2018.","volume":"43","author":"Dave","year":"2020","journal-title":"Diabetes Care"},{"issue":"11","key":"hrv200004r26","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1001\/jamacardio.2019.3796","article-title":"Implications of specialist density for diabetes care in the United States.","volume":"4","author":"Patel","year":"2019","journal-title":"JAMA Cardiol"},{"key":"hrv200004r27","doi-asserted-by":"publisher","first-page":"S98","DOI":"10.2337\/dc20-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes\u20142020.","volume":"43","author":"American Diabetes Association","year":"2020","journal-title":"Diabetes Care"},{"issue":"9","key":"hrv200004r28","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/s11892-018-1035-z","article-title":"Should metformin remain first-line medical therapy for patients with type 2 diabetes mellitus and atherosclerotic cardiovascular disease? an alternative approach.","volume":"18","author":"Harrington","year":"2018","journal-title":"Curr Diab Rep"},{"key":"hrv200004r29","doi-asserted-by":"publisher","first-page":"d7771","DOI":"10.1136\/bmj.d7771","article-title":"Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.","volume":"344","author":"Vilsb\u00f8ll","year":"2012","journal-title":"BMJ"},{"issue":"15","key":"hrv200004r30","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1001\/jama.2017.14752","article-title":"Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes: a randomized clinical trial.","volume":"318","author":"Davies","year":"2017","journal-title":"JAMA"},{"issue":"10","key":"hrv200004r32","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1016\/j.jacc.2019.12.063","article-title":"Effects of liraglutide on cardiovascular outcomes in patients with diabetes with or without heart failure.","volume":"75","author":"Marso","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"hrv200004r33","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1161\/CIRCULATIONAHA.119.041659","article-title":"Effect of once-weekly exenatide in patients with type 2 diabetes mellitus with and without heart failure and heart failure-related outcomes: insights from the EXSCEL trial.","volume":"140","author":"Fudim","year":"2019","journal-title":"Circulation"},{"issue":"3","key":"hrv200004r34","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1111\/dom.v22.3","article-title":"Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk.","volume":"22","author":"Husain","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"hrv200004r35","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/j.jacc.2018.01.047","article-title":"Prevalent and incident heart failure in cardiovascular outcome trials of patients with type 2 diabetes.","volume":"71","author":"Greene","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"hrv200004r36","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1001\/jama.2016.10260","article-title":"Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial.","volume":"316","author":"Margulies","year":"2016","journal-title":"JAMA"},{"issue":"1","key":"hrv200004r37","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/ejhf.2017.19.issue-1","article-title":"Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)\u2014a multicentre, double-blind, randomised, placebo-controlled trial.","volume":"19","author":"Jorsal","year":"2017","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"hrv200004r38","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.pcad.2019.07.005","article-title":"Mechanistic insights regarding the role of SGLT2 inhibitors and GLP1 agonist drugs on cardiovascular disease in diabetes.","volume":"62","author":"Garg","year":"2019","journal-title":"Prog Cardiovasc Dis"},{"issue":"24","key":"hrv200004r40","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy.","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"hrv200004r41","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1001\/jamainternmed.2019.3884","article-title":"Trends in aggregate use and associated expenditures of antihyperglycemic therapies among US Medicare beneficiaries between 2012 and 2017.","volume":"180","author":"Sumarsono","year":"2020","journal-title":"JAMA Intern Med"},{"issue":"15","key":"hrv200004r42","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-year follow-up of intensive glucose control in type 2 diabetes.","volume":"359","author":"Holman","year":"2008","journal-title":"N Engl J Med"},{"issue":"2","key":"hrv200004r43","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1093\/ndt\/gfz290","article-title":"Rationale and protocol of the Dapagliflozin And Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial.","volume":"35","author":"Heerspink","year":"2020","journal-title":"Nephrol Dial Transplant"},{"issue":"21","key":"hrv200004r44","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction.","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"issue":"10","key":"hrv200004r45","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1001\/jamainternmed.2016.1531","article-title":"Association of bile duct and gallbladder diseases with the use of incretin-based drugs in patients with type 2 diabetes mellitus.","volume":"176","author":"Faillie","year":"2016","journal-title":"JAMA Intern Med"},{"issue":"10","key":"hrv200004r46","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.2337\/dc19-0415","article-title":"Effects of liraglutide compared with placebo on events of acute gallbladder or biliary disease in patients with type 2 diabetes at high risk for cardiovascular events in the LEADER randomized trial.","volume":"42","author":"Nauck","year":"2019","journal-title":"Diabetes Care"},{"key":"hrv200004r13","unstructured":"A heart disease study of semaglutide in patients with type 2 diabetes (SOUL). ClinicalTrials.gov identifier: NCT03914326. Accessed May 14, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03914326"},{"key":"hrv200004r14","unstructured":"Effect of efpeglenatide on cardiovascular outcomes (AMPLITUDE-O). ClinicalTrials.gov identifier: NCT03496298. Accessed May 14, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03496298"},{"key":"hrv200004r31","unstructured":"Semaglutide effects on heart disease and stroke in patients with overweight or obesity (SELECT). ClinicalTrials.gov identifier: NCT03574597. Accessed May 14, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03574597"},{"key":"hrv200004r39","unstructured":"A research study to look at how semaglutide compared to placebo affects diabetic eye disease in people with type 2 diabetes (FOCUS). ClinicalTrials.gov identifier: NCT03811561. Accessed May 14, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03811561"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2766892\/jamacardiology_honigberg_2020_rv_200004_1602688160.41027.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,21]],"date-time":"2020-10-21T11:01:59Z","timestamp":1603278119000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2766892"}},"subtitle":["A Review"],"short-title":[],"issued":{"date-parts":[[2020,10,1]]},"references-count":46,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2020.1966","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10,1]]}}}